Cilengitide inhibits osteoclast adhesion through blocking the α_vβ₃-mediated FAK/Src signaling pathway

Area of Science:

• Bone Biology and Osteoclast Function
• Integrin Signaling in Bone Remodeling
• Pharmacological Inhibition of Osteoclast Activity

Background:

• Osteoclast actin cytoskeleton remodeling is crucial for bone resorption.
• Integrin αvβ3 is a key regulator of osteoclast function and bone matrix degradation.
• Cilengitide, an integrin inhibitor, has known anti-tumor effects but its role in osteoclasts is unclear.

Purpose of the Study:

• To investigate the effect of cilengitide on nuclear factor κB ligand-receptor activator (RANKL)-induced osteoclasts.
• To elucidate the underlying molecular mechanisms of cilengitide's action on osteoclasts.
• To assess cilengitide's impact on osteoclast formation, function, and adhesion.

Main Methods:

• Osteoclast differentiation induced by RANKL, treated with varying cilengitide concentrations.
• Assays included Cell Counting Kit-8, TRAP staining, F-actin ring formation, bone resorption, and adhesion.
• Molecular analysis involved immunoblotting and real-time fluorescent quantitative PCR for key signaling molecules.

Main Results:

• Cilengitide significantly inhibited osteoclast formation and function in a dose-dependent manner.
• No cytotoxic effects were observed at tested concentrations.
• Cilengitide downregulated osteoclast-relevant genes and key signaling molecules like FAK, integrin αvβ3, and c-Src.

Conclusions:

• Cilengitide effectively regulates osteoclast activity by inhibiting the integrin αvβ3 signaling pathway.
• This inhibition leads to diminished osteoclast adhesion and bone resorption.
• Cilengitide presents a potential therapeutic agent for conditions involving excessive osteoclast activity.